Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies (Tables)

3 Months Ended

Jun. 30, 2026

Notes Tables

Schedule of Other Current Assets [Table Text Block]

		*As of June 30,*				*As of March 31,*
		*2026*				*2026*

Prepaid insurance		$	282			$	396
Other prepaid expenses			222				181

Total other current assets		$	504			$	577

Schedule of Accrued Liabilities [Table Text Block]

		*As of June 30,*				*As of March 31,*
		*2026*				*2026*

Accrued compensation		$	-			$	593
Accrued clinical research costs			162				275
Accrued product development costs			175				30
Accrued professional fees			57				38
Other miscellaneous accrued expenses			53				69

Total accrued expenses		$	447			$	1,005

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

		*June 30,*
						*2025*
		*2026*				*(as revised)*

Equity based warrants to purchase common shares			209				4,173
Bridge financing warrants			1,194				1,194
Stock options granted under Company's incentive plan			645				11,842
Series A warrants			2,643				73,009
Series B warrants			70,366				-
Series C warrants			428,731				-
Representative warrants			8,606				4,383

Total potentially dilutive securities			512,394				94,601

Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]

		*Three Months Ended June 30, 2025*
		*Originally Filed*				*Adjusted for 1-for-21 Reverse Stock Split*

Net Loss (in thousands)		$	(3,337	)		$	(3,337	)
Loss per share - basic and diluted		$	(1.07	)		$	(22.69	)
Weighted average shares outstanding - basic and diluted (2025 is "as revised")			3,105,156				147,058